Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases


NCT01802645

Interventional

Phase 2

Active, not recruiting
CELIM2
The aim of this study is to investigate the following schedules for efficacy with regard to response rate in neoadjuvant treatment of patients with non-resectable liver metastases: - Cetuximab/FOLFOXIRI and cetuximab/FOLFIRI in patients with ras wild type tumours and - Bevacizumab/FOLFOXIRI and FOLFOXIRI in patients with ras mutant tumours.
Mar 31,2013
All
18 Years
N/A
91

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.